This campaign has now closed
Parkinson’s is a debilitating disease with limited treatment options, none of which are disease modifying. Previous studies showed cough suppressant ambroxol has promise at slowing Parkinson’s. Now, in our largest trial to-date, we will determine clinically if the drug can slow or stop Parkinson’s.
Categories
Beneficiaries
Situation
Around 145,000 people in the UK are living with Parkinson’s, a neurological condition caused by the loss of dopamine-producing nerve cells in the brain. Symptoms include tremor, muscle stiffness, exhaustion and depression. Parkinson’s is debilitating and can take away a person’s ability to live independently. Despite being the fastest growing neurological condition in the world, there is no cure and there are limited treatment options. We want to change this.
Solution
Previous studies have shown that ambroxol has neuroprotective properties. We are now going to test the drug in our largest ever phase 3 trial to see if ambroxol has the potential to slow the progression of Parkinson’s – something no other treatment can currently do. The trial will involve 330 people with Parkinson’s, across 10-12 clinical centres in the UK. Our sole aim is to find a cure – this trial could bring us closer to achieving this.
